Histone deacetylase 3-selective inhibitor RGFP966 ameliorates impaired glucose tolerance through ß-cell protection.

Lei, Lei; Bai, Guoliang; Wang, Xing; Liu, Shuainan; Xia, Jie; Wu, Song; Huan, Yi; Shen, Zhufang

Lei, Lei; Bai, Guoliang; Wang, Xing; Liu, Shuainan; Xia, Jie; Wu, Song; Huan, Yi; Shen, Zhufang.

Afiliación

Lei L; The State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Bai G; The State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Wang X; The State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Liu S; The State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Xia J; The State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Wu S; The State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Huan Y; The State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. Electronic address: huany@imm.ac.cn.
Shen Z; The State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. Electronic address: shenzhf@imm.ac.cn.

Toxicol Appl Pharmacol ; 406: 115189, 2020 11 01.

Article en En | MEDLINE | ID: mdl-32800772

Asunto(s)

Acrilamidas/uso terapéutico; Diabetes Mellitus Experimental/tratamiento farmacológico; Intolerancia a la Glucosa/tratamiento farmacológico; Inhibidores de Histona Desacetilasas/uso terapéutico; Histona Desacetilasas/metabolismo; Hipoglucemiantes/uso terapéutico; Fenilendiaminas/uso terapéutico; Acrilamidas/farmacología; Animales; Línea Celular; Diabetes Mellitus Experimental/genética; Diabetes Mellitus Experimental/metabolismo; Expresión Génica/efectos de los fármacos; Inhibidores de Histona Desacetilasas/farmacología; Hipoglucemiantes/farmacología; Secreción de Insulina/efectos de los fármacos; Células Secretoras de Insulina/efectos de los fármacos; Células Secretoras de Insulina/metabolismo; Masculino; Ratones Endogámicos C57BL; Ratones Endogámicos ICR; Fenilendiaminas/farmacología

Palabras clave

Histone deacetylase 3-selective inhibitor; Impaired glucose tolerance; Insulin secretion; Pre-diabetes; ß Cell

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Fenilendiaminas / Acrilamidas / Intolerancia a la Glucosa / Diabetes Mellitus Experimental / Inhibidores de Histona Desacetilasas / Histona Desacetilasas / Hipoglucemiantes Límite: Animals Idioma: En Revista: Toxicol Appl Pharmacol Año: 2020 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google